Rvl Pharmaceuticals Plc (RVLP) Earnings Report, Financial Results, Financial analysis

Rvl Pharmaceuticals Plc increased first quarter of 2023 net loss per share of $-0.12 compare to net loss per share of $-0.08 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.14 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.12	$ 9 Mill
$-0.04	$-13M -58.81 %

Rvl Pharmaceuticals Plc's Revenue fell by -58.81 % in first quarter of 2023 (Mar 31 2023) year on year, to $9 million and declined by -9.94 % sequentially.

Rvl Pharmaceuticals Plc is Expected to report next financial results on August 10, 2023.

More on RVLP's Income Statement

RVLP's NET INCOME

Rvl Pharmaceuticals Plc's in thefirst quarter of 2023 recorded net loss of $-11.612 million, an increase from net loss of $-6.821 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-18.319 million realized in previous quarter.

More on RVLP's Growth

Rvl Pharmaceuticals Plc Inventories
Inventories declined by -74.58 % to $0.21 million from I. Quarter a year ago, sequentially inventories fell by -72.83 %. In Mar 31 2023 company's net cash and cash equivalents decreased by $-12 million, capital expenditures fell by 4,729.63%, to $-1 millions compare to same quarter a year ago and fell by 86.29% from IV. Quarter (Dec 31 2022).

More on RVLP's Cash flow Statement

Earnings quality

Rvl Pharmaceuticals Plc does not pay out common stock dividend.

In trailing twelve-month period Rvl Pharmaceuticals Plc payed $ -0.31 cash per share, on a free-cash flow basis .

Book value fell by -29.75 % sequentially to $0.40 per share, -30.36% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -0.30 per share from $ -0.21.

Company issued 10.20 million shares or 11.44 % in Mar 31 2023.

• More on RVLP's Dividends

Market Capitalization (Millions)	87
Shares Outstanding (Millions)	99
Total Debt (Millions $)	4
Revenue (TTM) (Millions $)	37
Net Income (TTM) (Millions $)	-56
Cash Flow (TTM) (Millions $)	6
Capital Exp. (TTM) (Millions $)	-2
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Rvl Pharmaceuticals Plc does not pay out common stock dividend.

In trailing twelve-month period Rvl Pharmaceuticals Plc had negative $ -0.31 cash flow per share, on a free-cash flow basis .

Book value fell by -29.75 % sequentially to $0.40 per share, -30.36% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -0.30 per share from $ -0.21.

Company issued 10.20 million shares or 11.44 % in Mar 31 2023.

• More on RVLP's Balance Sheets

Market Capitalization (Millions)	87
Shares Outstanding (Millions)	99
Total Debt (Millions $)	4
Revenue (TTM) (Millions $)	37
Net Income (TTM) (Millions $)	-56
Cash Flow (TTM) (Millions $)	6
Capital Exp. (TTM) (Millions $)	-2
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Rvl Pharmaceuticals Plc

RVLP's Financial Statements and Analysis